
Sign up to save your podcasts
Or
Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA.
MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155
4.9
111111 ratings
Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA.
MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155
485 Listeners
118 Listeners
3,321 Listeners
1,093 Listeners
119 Listeners
508 Listeners
67 Listeners
5 Listeners
170 Listeners
11 Listeners
0 Listeners
1 Listeners
0 Listeners
5 Listeners
18 Listeners